patient
Sex age(years)
Number and size of tumor(cm)
Operation method
Operation time(min)
Duration, Number of portal vine occlusion(min) AFP (ng/l) CA-199 (ug/l) Neutrophil count (109/L) Lymphocyte count (109/L) Monocyte count (109/L) Eosinophils count (109/L) Basophil count (109/L)
Intrahepatic metastasis and time (months)
Treatment of intrahepatic recurrence, number, time(weeks)
Time of PM(months)
Survival time (months)
1 Male/43 3/14.4 OLR 210 0/0 2250 17.9 6.03 0.52 0.97 0.02 0.01 Yes/8 TACE/4 16 20
2 Female/41 2/0.4 OLR 305 1/15 66583 25.21 2.3 0.53 0.42 0.05 0.01 Yes/3.3 TACE/5 19 21
3 Female/48 1/3.6 OLR 130 0/0 970.3 16.99 3.64 1.15 0.26 0.10 0.00 Yes/48 TACE/3 61.1 91
4 Mela/45 2/8.4 OLR 240 1/11 2.72 31.54 12.28 2.28 0.63 0.05 0.00 No 6 15.5
5 Mela/51 1/4.5 OLR 180 0/0 177.14 8.37 1.54 0.69 0.17 0.10 0.00 No 21.1 38
6 Mela/53 1/8.5 OLR 230 0/0 2.63 39.6 5.27 1.18 0.37 0.11 0.01 Yes/2 RFCA/3 25.2 35
7 Mala/38 1/9.8 OLR 245 1/13 103.7 16.86 2.41 0.71 0.37 0.08 0.02 No 3.5 24.2
8 Mala/50 1/13 OLR 220 0/0 60.9 14.3 6.02 2.21 0.39 0.16 0.01 Yes/2 VPCC/2 13 29
9 Mala/38 1/3 OLR 135 0/0 12.33 13.94 2.08 1.16 0.39 0.04 0.01 No VPCC/5 11 20
10 Mela/51 1/7.2 OLR 270 0/0 1154 10.7 3.93 1.09 0.49 0.17 0.03 No 16.1 28
11 Mela/50 1/7.7 LLR 230 0/0 5404 23.82 3.62 1.05 0.03 0.07 0.00 No 16 23
12 Female/50 2/9.3 LLR 140 0/0 37.27 84.79 5.25 1.03 0.51 0.06 0.03 No 2.8 5
13 Mela/65 1/2 OLR 110 0/0 6.11 32.67 6.23 0.89 0.41 0.11 0.00 Yes/24 RFCA/1 56 80
14 Mela/45 1/7.7 OLR 140 0/0 92.25 8.12 2.91 1.90 0.28 0.04 0.02 Yes/3 TACE/3 22.1 62.5
15 Mala/54 1/6.7 OLR 255 0/0 3.79 40.36 3.91 1.26 0.23 0.12 0.02 No 9.4 18
16 Mela/50 1/12.7 OLR 240 0/0 58.9 15.2 5.73 2.41 0.42 0.18 0.02 Yes/1.7 TACE/5 14 30.8
17 Mela/47 1/10.7 OLR 194 1/18 75.89 34.03 2.75 1.28 0.27 0.05 0.00 Yes/5 TACE/1 7.8 11
18 Female/59 1/13.4 OLR 185 0/0 181.69 62.32 2.29 0.09 0.46 0.17 0.01 No 1.5 4.5
19 Male/26 1/3.8 LLR 125 1/17 3.22 2.00 2.91 1.33 0.13 0.08 0.00 No 25.4 33.1
20 Male/54 4/9.1 OLR 328 0/0 154.9 3.22 4.68 1.3 0.36 0.18 0.00 Yes/32 TACE/1 33 36.3
21 Mela/70 1/6.4 OLR 195 0/0 630.8 38.43 5.58 1.19 0.29 0.12 0.01 Yes/7 TACE/2 17 33.8
22 Mela/64 1/6.1 OLR 360 0/0 212.7 75.64 2.15 0.94 0.44 0.1 0.01 No 7.2 31.5
23 Mela/53 1/12.3 OLR 309 3/25 15764 69.3 4.11 1.15 0.36 0.28 0.03 No 4 13
24 Mela/44 1/7 OLR 200 0/0 169.6 12.7 2.67 1.08 0.42 0.08 0.02 Yes/2 TACE/3 7.5 31
25 Mela/47 1/12 OLR 210 1/15 77.12 35.91 2.31 1.17 0.29 0.15 0.00 Yes/6 RFCA/1 7.8 37.4
26 Mela/52 3/11.1 LLR 195 2/26 2.5 29.09 3.37 2.58 0.41 0.12 0.00 Yes/9 RFCA/1 19.5 30.2
27 Mela/52 2/12 LLR 210 2/25 21.4 29.9 2.91 1.86 0.33 0.21 0.02 Yes/10 TACE/1 17 25
28 Mela/66 1/6.4 OLR 200 3/30 1.78 53.1 4.19 1.95 0.24 0.04 0.00 No 12.5 29
29 Mela/38 1/8.4 OLR 187 1/6 3.16 29.6 3.21 1.37 0.65 0.09 0.02 No TACE/1 1.6 10
30 Mela/49 2/4.5 LLR 190 0/0 3.97 43.58 2.47 0.63 0.16 0.19 0.00 No 6 25
31 Female/60 1/13.4 OLR 185 0/0 1503 69.4 2.63 1.64 0.41 0.22 0.02 No 1.6 10.4
32 Female/60 2/10.1 OLR 290 0/0 121000 72.1 2.08 0.62 0.33 0.03 0.03 No 2.7 7
33 Mela/49 3/10.4 OLR 175 1/8 1.06 1.21 2.63 1.22 0.35 0.01 0.01 No 4.2 6.7